Evidence map›Paper›PMID 40862711›Full record

ReviewCells2025

Recent Therapies and Biomarkers in Mucinous Ovarian Carcinoma.

Grzegorz Przywara, Oliwia Biegańska, Emilia Biczak, Aleksander Białoń, Dominik Fidorowicz, Alicja Dankowska, Zofia Łapińska, Julita Kulbacka

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grzegorz PrzywaraFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.ORCID 0009-0004-4710-0663
Oliwia BiegańskaFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.ORCID 0009-0006-0442-6211
Emilia BiczakFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.
Aleksander BiałońFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.
Dominik FidorowiczFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.ORCID 0009-0005-2184-4004
Alicja DankowskaFaculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland.
Zofia ŁapińskaDepartment of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Julita KulbackaDepartment of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.ORCID 0000-0001-8272-5440

Funding

Statutory Funds of Wroclaw Medical University SUBZ.D260.25.027.
6 · The paper itself

Abstract

Mucinous ovarian carcinoma (MOC) represents a rare and biologically distinct subtype of ovarian cancer, characterized by poor response to standard platinum-based chemotherapy and a unique molecular profile, including frequent KRAS mutations and HER2 amplifications. Recent advancements in targeted therapy, such as HER2 inhibitors and

Indexed as

Adenocarcinoma, MucinousBiomarkers, TumorOvarian NeoplasmsFemaleHumansImmunotherapyMolecular Targeted TherapyBiomarkers, Tumorcheckpoint inhibitorsHER2immunotherapyKRASmucinous ovarian carcinomaPARP inhibitorssynthetic lethalitytargeted therapyWnt/β-catenin pathway

Identifiers

PMID40862711
PMCPMC12384067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.